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Abstract
Aims: Although pelvic radiotherapy is an effective treatment for various malignancies, around half of patients develop signiﬁcant gastrointestinal problems.
These symptoms often remain undetected, despite the existence of effective treatments. This study developed and reﬁned a simple screening tool to detect
common gastrointestinal symptoms in outpatient clinics. These symptoms have a signiﬁcant effect on quality of life. This tool will increase detection rates and so
enable access to specialist gastroenterologists, which will in turn lead to improved symptom control and quality of life after treatment.
Materials and methods: A literature review and expert consensus meeting identiﬁed four items for the ALERT-B (Assessment of Late Effects of RadioTherapy -
Bowel) screening tool. ALERT-B was face tested for its usability and acceptability using cognitive interviews with 12 patients experiencing late gastrointestinal
symptoms after pelvic radiotherapy. Thematic analysis and probe category were used to analyse interview transcripts. Interview data were presented to a group
of experts to agree on the ﬁnal content and format of the tool. ALERT-B was assessed for reliability and tested for validity against the Gastrointestinal Symptom
Rating Scale in a clinical study (EAGLE).
Results: Overall, the tool was found to be acceptable in terms of wording, response format and completion time. Participant-reported experiences, including
lifestyle modiﬁcations and the psychological effect of the symptoms, led to further modiﬁcations of the tool. The reﬁned tool includes three questions covering
rectal bleeding, incontinence, nocturnal bowel movements and impact on quality of life, including mood, relationships and socialising. ALERT-B was successfully
validated against the Gastrointestinal Symptom Rating Scale in the EAGLE study with the tool shown broadly to be internally consistent (Cronbach’s a ¼ 0.61
and all item-subscale correlation [Spearman] coefﬁcients are > 0.6).
Conclusion: The ALERT-B screening tool can be used in clinical practice to improve post-treatment supportive care by triggering the clinical assessment of
patients suitable for referral to a gastroenterologist.
 2016 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Pelvic radiotherapy is an effective treatment for a range
of malignancies, including those affecting the gynaeco-
logical (uterus, cervix, vagina and vulva), urological (pros-
tate and bladder) and gastrointestinal (rectum and anus)
tracts [1]. Although efﬁcacious, it is recognised that pelvic
radiation can lead to gastrointestinal, urological and
psycho-sexual symptoms in the months or years afterd. This is an open access article under the CC BY-NC-ND license (http://
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treated, with no simple tool available to easily identify pa-
tients [3]. Here we report on the development of a simple
screening tool, ALERT-B (Assessment of Late Effects of
RadioTherapy - Bowel), to be used in oncology clinics to
identify patients with ongoing gastrointestinal symptoms
after pelvic radiation for cancer.
In excess of 20 abdominal symptoms have been
described after pelvic radiotherapy, including diarrhoea,
rectal bleeding, abdominal pain, and faecal incontinence
[3,4]. Each symptom can have many causes and patients
often report several symptoms [3]. Bowel symptoms can be
related to treatment dose of radiotherapy, cancer type,
cancer stage, length of time since treatment or conversely it
can be unrelated to radiotherapy [5].
Acute symptoms caused by inﬂammation and mucosal
damage tend to begin around the second week of treat-
ment and often settle within 3 months [6]. Symptoms
that persist or appear after this time frame as a conse-
quence of ischaemia and ﬁbrosis are considered to be late
or chronic effects [6]. Studies have suggested that around
90% of patients have a change in bowel function, of which
up to 40% describe these symptoms to be moderate or
severe with an impact on quality of life [3,7]. The inci-
dence of these symptoms is increasing with improved
cancer survivorship and increased availability of radio-
therapy [8]. These symptoms affect various aspects of
patients’ lives, including physical, psychological and social
functioning [7].
Although cellular pathological changes induced by
radiotherapy cannot be reversed, identiﬁed gastrointestinal
symptoms can be treated by correcting the functional
physiological changes induced by radiotherapy [3,9].
Gastroenterology healthcare professionals can systemati-
cally investigate these symptoms and suggest medical, di-
etary or endoscopic interventions that can help to alleviate
these distressing complaints [2,10].
Chronic radiation-induced late effects, caused by
vascular damage, are substantially more common than
healthcare professionals generally recognise [3], and are
under-reported by patients [3]. There are several possible
reasons for this. Patients may be too embarrassed to
mention their symptoms or feel that they are an inevitable
consequence of their treatment or age [7]. Patients may also
believe that there are other more important issues to
discuss during time-limited consultations [6]. A number of
clinicians may also believe that few treatment options are
available for these patients, thus identiﬁcation of gastroin-
testinal symptoms will have limited clinical beneﬁt [6].
Consequently, gastrointestinal symptoms may not be
routinely enquired about and if reported may not be linked
with previous radiotherapy [11].
For a screening tool to be effective in a busy clinical
setting, the questionnaire needs to be succinct and
straightforward to administer. The Late Effects on Normal
Tissue Subjective, Objective, Management, and Analytic
(LENT-SOMA) questionnaire (now largely superseded by
Common Terminology Criteria for Adverse Events [CTCAE])
[12], was developed to assess awide range of problems afterPlease cite this article in press as: Taylor S, et al., The Three-item ALERT-B
Gastrointestinal Symptoms after Pelvic Radiotherapy in Cancer Survivors,radiotherapy. Therefore, despite efforts to reduce the length
of this questionnaire (in particular, for prostate cancer pa-
tients for the present study) [13], such LENT-SOMA ques-
tionnaires (and associated variants) are too long to be used
routinely as a screening tool [14]. Other symptom-based
scoring systems are also either too lengthy (e.g. the modi-
ﬁed Inﬂammatory Bowel Disease Questionnaire [IBDQ] [15]
with 32 items and the Gastrointestinal Symptom Rating
Scale [GSRS] [16] with 15 items) or they focus on just one
symptom (e.g. the Vaizey Incontinence Questionnaire with
seven items focussing on bowel continence) [17]. Therefore,
there is a need for a simple screening tool that can be used
in clinical practice. Cognitive interviewing has been
empirically validated as a technique for pretesting ques-
tionnaires and screening tools [18]. It can be used to identify
issues pertaining to the content, format and interpretation
of questions using a small number of selected participants
who provide in-depth information about the screening tool
[19,20]. The aims of this study were to design, test and
validate a simple screening tool that can effectively detect
patients with ongoing gastrointestinal symptoms that have
developed after pelvic radiotherapy for cancer.Materials and Methods
Phase One
The ALERT-B screening tool was developed and vali-
dated in four phases (Figure 1). Phases one to three were
part of the DESIGNER study (DEveloping a SImple
screening tool to detect chronic GastrointestiNal symp-
toms after pelvic radiothERapy in cancer survivors) and
phase four was part of the EAGLE study (Improving the
Wellbeing of Men by Evaluating and Addressing the
Gastrointestinal Late Effects of Radical Treatment for
Prostate Cancer). During phase one, an initial expert
consensus day was held in April 2013 to generate the
screening tool items. A range of existing questionnaires
were reviewed, including the Vaizey Incontinence Ques-
tionnaire, LENT-SOMA, GSRS and the modiﬁed IBDQ
[14e17], for post-radiotherapy patients as well as those
that assess gastrointestinal symptoms and quality of life.
Andreyev et al.’s suggested screening questions were also
reviewed during the consensus meeting [2]. A patient
representative gave advice on acceptable wording for
either self-administration of the tool or with assistance
from healthcare professionals.
Phase Two
In phase two, the newly developed ALERT-B screening
tool was face tested for its usability and acceptability using
cognitive interviewing with a representative patient group.
The study aimed to interview around 10e15 participants,
based on Willis’ recommended sample size [18].
Eligible patients for the cognitive interviews in phase
two of the study were identiﬁed and approached by
healthcare professionals at oncology and gastroenterologyQuestionnaire Provides a Validated Screening Tool to Detect Chronic
Clinical Oncology (2016), http://dx.doi.org/10.1016/j.clon.2016.06.004
Phase One: Item GeneraƟon at a Consensus meeƟng
8 aƩendees comprised of: 
• 2 oncologists who treat malignancies using pelvic radiaƟon; 
• 2 gastroenterologists with experience in managing the late 
radiaƟon gastrointesƟnal eﬀects; 
• 3 members of research staﬀ; 
• 1 paƟent representaƟve. 
Phase Two: Face TesƟng for Acceptability 
12 parƟcipants consented to cogniƟve interviews 
Phase Three: Tool Refinement at Final Consensus meeƟng
9 aƩendees largely comprised of the same as those who aƩended 
the first consensus meeƟng: 
•3 oncologists; 
•3 gastroenterologists; 
•2 members of research staﬀ; 
•1 paƟent representaƟve. 
Phase Four: Psychometric ValidaƟon 
The ALERT-B screening tool was validated against the 
GastrointesƟnal Symptom RaƟng Scale (GSRS) in a current 
prostate cancer study (EAGLE).  
Fig 1. Study proﬁle. The development of the ALERT-B screening tool
consists of four phases involving two expert consensus meetings,
qualitative interviews with participants who developed late
gastrointestinal symptoms after pelvic radiotherapy and a validation
phase.
S. Taylor et al. / Clinical Oncology xxx (2016) 1e9 3clinics from two hospitals in South Wales. Inclusion
criteria included patients 16 years or older, received
radical pelvic radiotherapy more than 3 months previ-
ously, with no evidence of current malignant disease,
experiencing chronic gastrointestinal symptoms since
receiving pelvic radiotherapy, able to give informed con-
sent to participate in the study and able to understand
and communicate to the extent needed to participate in
the interview. Exclusion criteria included evidence of
active malignant disease, patients under secondary care
review for an active known gastrointestinal disease, any
factor that affects communication and comprehension,
and age below 16 years.
All eligible participants were given a letter and a
participant information sheet until the sample size was
met. Participants completed and posted the return slip on
the invitation letter to express interest in the study and
they were then contacted by the researcher after 24 hours
to arrange an interview. Interviews were conducted by one
researcher with an academic clinical background, and took
place either in the participant’s home or a quiet clinic space
according to preference. The researcher gained writtenPlease cite this article in press as: Taylor S, et al., The Three-item ALERT-B
Gastrointestinal Symptoms after Pelvic Radiotherapy in Cancer Survivors,informed consent from all participants before the start of
the interview. Participants’ clinical and demographic in-
formationwere recorded by the researcher or clinician from
the study team.
In line with sample size recommendations [18], 12 pa-
tients (six men and six women) were recruited and inter-
viewed by the researcher between October 2013 and
January 2014. The ﬁnal decision to close recruitment was
based on the researcher’s experience and when no new
themes were mentioned by participants. Three of the in-
terviews took place at an outpatient clinic and nine in the
participants’ homes. All those who were recruited
completed the study with no drop outs. This cognitive
interview study was approved by the NorthWales Research
Ethics Committee (REC) (Central & East) Proportionate Re-
view Sub-Committee (reference 13/WA/0243).
The cognitive interviews assessed participants’ under-
standing of instructions and questions in the screening tool,
ability to make a judgement about an appropriate response
and response format. A concurrent debrieﬁng approach was
used with a structured interview guide, developed specif-
ically for this study. This interview guide used preselected
probes, designed to ﬁt alongside coding categories to test
the screening tool in speciﬁc domains. ‘Verbal probing’
techniques were used when speciﬁc elaboration regarding
aspects of the question were required [18]. Speciﬁc verbal
probes were used to address individual difﬁculties as they
arose. Recognised probe categories were used, such as
comprehension, paraphrasing and recall to assess issues,
such as word comprehension. Before the interview, the
researcher observed and timed the participants and noted if
participants seemed to struggle with any aspects of the
screening tool.
The interviews were digitally recorded and transcribed
verbatim, and the transcripts were imported into NVivo 10
(QSR) qualitative analysis software for coding [22]. The-
matic analysis was used to analyse the interview transcripts
and allowed the researcher to undertake both deductive
and inductive analyses [23]. The deductive analysis helped
to search for speciﬁc items and inductive analysis explored
unsolicited comments made by the participants (see
Supplementary Material).
Phase Three
In phase three, a second and ﬁnal consensusmeetingwas
held in February 2014 to review and reﬁne the tested
screening tool based on the ﬁndings of phase two. Expert
opinion and interview results data were used to review and
reﬁne the screening tool in readiness for use in local
practice.
Phase Four
In phase four, ALERT-B was psychometrically validated
against GSRS in the EAGLE study. The EAGLE study aims to
set up and test a new gastroenterology service at three UK
sites that will systematically investigate and treat prostate
cancer patients who develop late gastrointestinalQuestionnaire Provides a Validated Screening Tool to Detect Chronic
Clinical Oncology (2016), http://dx.doi.org/10.1016/j.clon.2016.06.004
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were completed by prostate oncology clinics to determine
eligibility to the study. GSRS is a disease-speciﬁc patient
completed instrument of 15 items combined into ﬁve
scales relating to abdominal pain, reﬂux, diarrhoea, indi-
gestion and constipation. The reliability and validity of
GSRS have previously been tested [16,21]. Recruitment of
subjects was initially constrained to cover a 6 month
period, with an aim to recruit around 150 participants. This
sample size was considered more than sufﬁcient for the
purposes of an analysis of validity using Spearman corre-
lation coefﬁcients.
Inclusion criteria for phase four included patients
attending oncology clinics who received radiotherapy at
least 6 months previously and were aged over 18 years.
Exclusion criteria included any factor that affects
communication or comprehension, lacking the capacity
to consent and a known cancer recurrence. Prostate
cancer patients at three oncology departments across the
UK were screened for late gastrointestinal effects of pel-
vic radiotherapy using the ALERT-B screening tool and
GSRS. Patients identiﬁed with gastrointestinal symptoms
were then referred to a new gastroenterology service.
Between June 2015 and January 2016 questionnaire re-
sponses from 164 prostate cancer patients recruited to
the EAGLE study were analysed. The ages of men
recruited ranged from 54 to 87 years with a mean age of
73 years. The validation phase as part of the EAGLE study
was approved by North West Liverpool East REC (refer-
ence 14/NW1206).
Validation of ALERT-B was analysed in terms of internal
consistency reliability, item-scale correlation coefﬁcients
and factor analysis. Internal consistency reliability was
assessed by determining the Cronbach’s a coefﬁcient with
a  0.6e0.7 indicating (broadly) adequate levels of reli-
ability. Item data were not normally distributed and so the
Spearman rank correlation coefﬁcient r of each item score
with respect to the mean value for ALERT-B was deter-
mined. Values for the item-scale correlation coefﬁcient that1. Do you have diﬃculty in controlling your bowels, suc
 - Needing to go straight away/can’t wait 
 - Having to get up at night to poo 
 - Having accidents, such as soiling 
2. Do you have bleeding from your boƩom? 
3. Have you had to adapt your lifestyle because of your
(e.g., do you avoid any acƟviƟes or situaƟons- 
conƟnence supplies, spare clothing or a radar k
dietary changes? Have your symptoms aﬀected
4. Do your bowel and tummy problems aﬀect your moo
Fig 2. Version 1 of ALERT-B screening tool questions. Version 1 of the A
sponses. The questions were designed to identify gastroenterology symp
Please cite this article in press as: Taylor S, et al., The Three-item ALERT-B
Gastrointestinal Symptoms after Pelvic Radiotherapy in Cancer Survivors,were 0.6 were taken to indicate high levels of consistency
for the item.
An additional analysis used exploratory factor analysis
[24,25] of both GSRS and ALERT-B to identify highly corre-
lated items. However, this analysis is not discussed at length
here due to size considerations of this article, although re-
sults for factor loadings from this analysis are available as
Supplementary Material.Results
Phase One
The ﬁrst draft of the screening tool was generated
(Figure 2) during the ﬁrst expert consensus meeting.
Screening tool items were selected for immediate clinical
relevance with the intention that a ‘yes’ response to any
single itemwould trigger clinical consideration for a referral
to gastroenterology.Phase Two
In total, 12 participants were interviewed during phase
two. Table 1 details the age and diagnosed malignancies
of the participants. The ages at which participants’ pelvic
malignancies were diagnosed ranged from 35 to 74 years,
with a mean age at diagnosis of 60 years. Just under half
the sample (n ¼ 5) had been diagnosed with prostate
cancer.
Overall, participants were positive about the ALERT-B
screening tool and provided suggestions for screening tool
reﬁnement, including adjustments to the wording and
layout. The main issues and solutions covered in the in-
terviews are outlined and evidenced below with interview
excerpts as illustrative examples. All excerpts are fully
anonymised. A summary of the ﬁndings is presented in
Table 2.h as:
 bowel or tummy symptoms? 
travel, work, social life or hobbies? Do you take 
ey with you when you go out? Have you made any 
 any caring duƟes?) 
d, social funcƟoning or relaƟonships? 
LERT-B screening tool consists of four questions with ‘yes’ or ‘no’ re-
toms that are suitable for referral to a gastroenterologist.
Questionnaire Provides a Validated Screening Tool to Detect Chronic
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Table 1
Qualitative interview participants
Participant demographics No. participants
Age 59 years 1
60e69 years 7
 70 years 4
Malignancy Prostate 5
Endometrial 2
Uterine 2
Cervical 1
Anal 1
Liposarcoma 1
Cancer treatment Radiotherapy alone 1
Radiotherapy and surgery 7
Radiotherapy and hormonal treatment 3
Radiotherapy and chemotherapy 1
Table 2
Summary of ﬁndings presented at the second consensus meeting in phase three
Screening tool feedback Participant experiences
Screening tool question 1: Do you have difﬁculty in controlling your bowels, such as: needing to go straight away/can’t wait, having to
get up at night to poo, having accidents such as soiling.
 Use of colloquial language in the question helped participants
to answer the question (Participants 5; 8);
 The sub-questions helped participants to consider their
bowel control (Participants 1e12).
 Difﬁculties in bowel control was a commonly reported
symptom during the interviews (Participants 1e6; 8e11);
 Participants had no difﬁculty recalling their symptoms due to
concerns about their ability to control their bowels (Partici-
pants 1; 3e5; 7; 9e12).
Screening tool question 2: Do you have bleeding from your bottom?
 Differences in answer threshold emerged as to when a
participant would indicate they had rectal bleeding on the
screening tool (Participants 2; 5; 6);
 For clarity the question could stipulate that any amount or
frequency of blood should prompt a yes answer (Participant
9).
 Rectal bleeding was considered a frightening concept
(Participant 6);
 Participants described an increase awareness in looking for
rectal bleeding following their cancer diagnosis (Participant
6);
 A fear of missing blood in the stool was reported (Participant
9).
Screening tool question 3: Have you had to adapt your lifestyle because of your bowel or tummy symptoms? (e.g. do you avoid any
activities or situations - travel, work, social life or hobbies? Do you take continence supplies, spare clothing or a radar key with you
when you go out? Have you made any dietary changes? Have your symptoms affected any caring duties?)
 Uncertainty over a radar key (Participants 2; 6; 7; 10);
 Uncertainty over the inclusion of caring duties in the question
(Participants 5; 11);
 The list of adaptations helped focus answers (Participants 1
e12).
 Suffering from bowel symptoms had resulted in a change in
lifestyle and activities (Participants 1e12);
 Experiences of social isolation (Participants 1; 2; 4; 8; 9; 11;
12);
 Cancer diagnosis may result in positive health behaviour
changes (Participant 5).
Screening tool question 4: Do your bowel and tummy problems affect your mood, social functioning or relationships?
 Uncertainty over the term ‘social functioning’ (Participant 2);
 The question was considered important as suffering from
bowel symptoms can have a great impact on social func-
tioning (Participants 1e12);
 Even though the question covers a sensitive subject it is still
important to ask (Participants 1e12).
 Symptom burden affected mood, relationships and general
wellbeing (Participants 1e12);
 Relief at the opportunity to discuss symptom impact (Par-
ticipants 3; 5; 6; 8; 10);
Overall comments
 Increase font size (Participant 6);
 Reformat the tool to make it more visually appealing (Participant 6);
Include an explanatory note to contextualise the screening tool (Participant 5).
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A summary of the main ﬁndings from the cognitive in-
terviews was used to reﬁne the screening tool during the
ﬁnal consensus meeting in phase three. Each question and
the overall layout were reviewed in turn until the ﬁnal
version of the ALERT-B screening tool was agreed. At-
tendees of the ﬁnal consensus meeting decided to remove
the urgency question as it was thought this would be have
an impact on daily life and would be covered by the ﬁnal
question. A summary of the modiﬁcations can be seen in
Table 3, and the questions in the ﬁnal version of the
screening tool in Figure 3.
Phase Four
The ﬁnal version of the ALERT-B screening tool, as seen in
Figure 3, was psychometrically validated against GSRS. In
total, 164 patients completed ALERT-B and GSRS. Missing
data made up less than 2% for all items. The reliability of the
scales for GSRS established using Cronbach’s a were found
to be: abdominal pain (a¼ 0.29), reﬂux (a¼ 0.74), diarrhoea
(a ¼ 0.79), indigestion (a ¼ 0.79) and constipation
(a ¼ 0.55). The reliability of ALERT-B was found to be
a ¼ 0.61. Item-scale correlations using Spearman’s corre-
lation coefﬁcient (r) for ALERT-B were: ‘get up at night to
poo’ (r ¼ 0.67), ‘accidents, such as soiling or wet wind’
(r¼ 0.76), ‘blood fromyour bottom’ (r¼ 0.61) and ‘bowel orTable 3
An overview of the development of the ALERT-B screening tool from p
Wording used in version 1 of the
screening tool
Suggested change
1. Do you have difﬁculty in control-
ling your bowels, such as:
 Needing to go straight away/can’t
wait;
 Having to get up at night to poo;
 Having accidents, such as soiling.
- Deﬁne the ter
controlling your
- Clarify the term
‘soiling’.
- Remove ‘needin
away/can’t wait’
one.
2. Do you have bleeding from your
bottom?
- Clarify that par
answer yes for a
rectal bleeding, e
3. Have you had to adapt your life-
style because of your bowel or
tummy symptoms?
(e.g. do you avoid any activities or
situations - travel, work, social life or
hobbies? Do you take continence
supplies, spare clothing or a radar key
with you when you go out? Have you
made any dietary changes? Have your
symptoms affected any caring
duties?)
- Remove radar
duties from the l
- Avoid use of the
4. Do your bowel and tummy prob-
lems affect your mood, social
functioning or relationships?
Merge question 3 an
Please cite this article in press as: Taylor S, et al., The Three-item ALERT-B
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correlation matrix for GSRS scales and items in ALERT-B is
shown in Table 4. The strongest correlations are generally
signiﬁcant between items in ALERT-B and the bowel-related
scores, as shown in Table 4.
Spearman correlation coefﬁcients between ALERT-B
items and the GSRS abdominal pain, diarrhoea and con-
stipation scales are of generally moderate strength (i.e. of
order: r ¼ 0.3e0.5) and they are statistically signiﬁcant (i.e.
P < 0.05). By contrast, Spearman correlation coefﬁcients
between ALERT-B items and the other GSRS scales (the
GSRS reﬂux scale, in particular) are often smaller in
magnitude and they are not always statistically signiﬁcant
(i.e. P > 0.05). Finally, results of exploratory factor analysis
were found to agree with these analyses of correlation co-
efﬁcients presented in Table 4. In particular, ALERT-B items
were found to correlate strongly only with items in the
GSRS scale that relate to bowel symptoms. However, we
note that factor analysis is not discussed in detail here,
although a table of factor loadings is available in the
Supplementary Material.Discussion
This study showed that the ALERT-B screening tool was
considered by participants to offer an effective way to
inform healthcare professionals of their bowel symptoms tohase three of the study
Finalised screening tool post-
consensus meeting
m ‘difﬁculty in
bowels’.
s ‘accidents’ and
g to go straight
from question
1. Do you have any difﬁculty in
controlling your bowels (having a
poo), such as:
 Having to get up at night to poo;
 Having accidents, such as soiling or
a sensation of wetness (“wet
wind”).
ticipants should
ny amount of
ven if it is once.
2. Have you noticed any blood from
your bottom recently?
(any amount or frequency)
key and caring
ist of examples.
term lifestyle.
3. Do you have any bowel or tummy
problems that affect your mood,
social life, relationships or any
other aspect of your daily life?
(e.g. do you avoid any activities or
situations - travel, work, social life or
hobbies? Do you take continence
supplies or spare clothing with you
when you go out? Have you made any
dietary changes? Do you need to allow
for frequency or urgency of needing
the toilet?)
d 4 together. Question 4 removed.
Questionnaire Provides a Validated Screening Tool to Detect Chronic
Clinical Oncology (2016), http://dx.doi.org/10.1016/j.clon.2016.06.004
Fig 3. Final version of the ALERT-B screening tool. The results of the qualitative interviews were discussed during the second expert consensus
and used to amend and ﬁnalise the ALERT-B screening tool.
S. Taylor et al. / Clinical Oncology xxx (2016) 1e9 7prompt further discussion. Participants felt the tool was
easy to use and contained speciﬁc strengths; particularly,
the concise formatting with tick boxes enabling speedy
completion of the tool. By asking affected patients to com-
plete the initial version of ALERT-B and take part in a
qualitative interview, unique insights were gained on the
extent to which the tool is understandable, usable and
pertinent to this patient group. These perspectives
encompassed issues ranging from comprehension of
wording, perception of the importance and relevance of
questions, and the patient narratives of subjective symptom
experiences that reinforce the value and necessity of the
screening tool.
This study used cognitive interviewing to allow potential
problems with the screening tool to be identiﬁed before its
use in larger studies or in clinical practice [26]. By under-
taking individual interviews issues could be explored
sensitively [27]. Overall there was consensus between theTable 4
Spearman’s correlation coefﬁcient (r) between GSRS scales and items i
GSR
Abd
ALERT-B Get up at night to poo 0.29
Accidents, such as soiling or wet wind 0.29
Blood from your bottom 0.25
Bowel or tummy problems affecting your daily life 0.35
** Correlation is signiﬁcant at the 1% level (two-tailed).
* Correlation is signiﬁcant at the 5% level (two-tailed).
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screening tool. Participants’ narratives on their experiences
of living with late gastrointestinal symptoms helped pro-
vide insightful feedback on the screening tool and high-
lighted the importance of identifying this patient group.
The interviews provided an insight into the impact of late
bowel symptoms after pelvic radiotherapy on quality of life
(see Supplementary Material). In line with current litera-
ture, the participant perspectives gathered during this
study showed that bowel symptoms caused by pelvic
radiotherapy have a signiﬁcant impact on quality of life
[6,7]. All participants reported a reduction in their quality of
life, regardless of the malignancy they had received treat-
ment for, or the bowel symptoms they reported.
A limitation of the qualitative study was that the
cognitive ability of participants was not measured. Varia-
tions in cognitive ability may have restricted their ability to
complete the screening tool and may be affected byn ALERT-B
S scale
ominal pain Reﬂux Diarrhoea Indigestion Constipation
5** 0.124 0.311** 0.232** 0.206**
7** 0.183* 0.497** 0.455** 0.249**
3** 0.188* 0.157* 0.349** 0.257**
7** 0.102 0.47** 0.339** 0.366**
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Furthermore, research has shown that cognitive in-
terviews are limited by participants’ ability to articulate
and discuss their thought processes [32]. Where partici-
pants did not report any difﬁculties with a particular
question of the screening tool, it is still not possible to infer
that all participants understood the question in the same
way [32]. Another limitation is that the patients who
responded to the invitation to participate in the study may
have been a self-selected group who were willing to
discuss their bowel symptoms. Consequently, the sample
may not be fully representative of patients with late bowel
effects following pelvic radiotherapy.
The validation of ALERT-B has been successful. As ex-
pected, values for Cronbach’s a for GSRS scales are gener-
ally high, with only the abdominal pain scale somewhat
lower, as seen elsewhere [16,21]. Cronbach’s a was found
to be given by a ¼ 0.61 for ALERT-B, which is slightly lower
than the generally accepted cut-off for ‘adequate’ given by
a value of a  0.7. However, it is well known that Cron-
bach’s a is strongly affected by the number of items
included in the calculation (with higher numbers of items
tending to increase the value of a) and so this value
probably does indicate ‘adequate’ levels of reliability for
the three items in ALERT-B. Furthermore, item-scale cor-
relations were high, r > 0.6, and so these results again
indicate broadly that ALERT-B is internally consistent. The
correlation matrix of GSRS scales with ALERT-B items
indicated that strongest correlations occurred between
GSRS diarrhoea scale and the items in ALERT-B, whereas
the weakest correlations occurred between GSRS reﬂux
scale and the items in ALERT-B. These results make sense
because ALERT-B deals only with bowel problems. Hence,
validity is established for both convergent and discrimi-
native validity.
Results of exploratory factor analysis support those re-
sults of the analysis of correlation coefﬁcients discussed
above. In particular, factor analysis showed that the GSRS
reﬂux scale tends to have the weakest correlations with the
items in ALERT-B. Again, this result is explicable as ALERT-B
only focusses on bowel symptoms. Factor analysis also
showed that ALERT-B ‘Bowel or tummy problems affecting
your daily life’ correlates strongly within many of the items
in GSRS and also ALERT-B, and is suggestive of how different
gastrointestinal symptoms might inﬂuence the patients’
daily lives. However, exploratory factor analysis was not
discussed in detail in this article, although a table of factor
loadings is available (see Supplementary Material). Work
carried out across the four phases has designed, tested and
validated the ALERT-B tool. Using mixed methods across
two studies has helped to develop and robustly test a new
screening tool that is tailored to the needs of this patient
group. The questions developed through the consensus
group meetings and patient feedback have created a patient
friendly screening tool that is largely similar to the clinical
questions suggested by Andreyev et al. [2]. Participants who
were cognitively interviewed felt this screening tool would
help to initiate discussions with healthcare professionals
about their bowel symptoms.Please cite this article in press as: Taylor S, et al., The Three-item ALERT-B
Gastrointestinal Symptoms after Pelvic Radiotherapy in Cancer Survivors,Conclusions
This study designed, tested and validated the ALERT-B
screening tool that was acceptable to patients. The range
and content of the questions offer clinicians an under-
standing of the impact the symptoms have on patients’
quality of life and highlight red ﬂag symptoms that require
further discussion with the patient. The study also high-
lights the importance of routinely screening all patients for
bowel symptoms in the post-pelvic radiotherapy treatment
phase to enable appropriate management to occur.
Acknowledgements
Phases one to three were funded by Tenovus Cancer Care
(grant reference: TIG 2012-16).
The work represented in this manuscript, including the
posts of AN, SS, and AB , is supported by core funding from
Marie Curie to the Marie Curie Palliative Care Research
Centre, Cardiff University (grant reference: MCCC-FCO-14-C).
Validation of ALERT-B was conducted as part of the EA-
GLE study, funded by Prostate Cancer UK (Grant Reference
250-55). We would like to thank all the participants for the
time they have given to the study. Participating centres:
DESIGNER study - Cardiff and Vale University Health Board,
Cardiff, UK e J. Green, J. Turner. Velindre NHS Trust, Cardiff,
UKe L. Hanna, J. Staffurth, R. Adams. EAGLE Study - Velindre
NHS Trust, Shefﬁeld Teaching Hospitals NHS Foundation
Trust and Brighton and Sussex University Hospitals NHS
Trust.Appendix A. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.clon.2016.06.004.
References
[1] Gami B, Harrington K, Blake P, et al. How patients manage
gastrointestinal symptoms after pelvic radiotherapy. Aliment
Pharmacol Therap 2003;18:987e994.
[2] Andreyev H, Davidson S, Gillespie C, Allum W, Swarbrick E.
Practice guidance on the management of acute and chronic
gastrointestinal problems arising as a result of treatment for
cancer. Gut 2012;61:179e192.
[3] Andreyev H. Gastrointestinal problems after pelvic radio-
therapy: a new understanding to improve management of
symptomatic patients. Lancet Oncol 2007;8:1007e1017.
[4] Andreyev H. Gastrointestinal problems after pelvic radio-
therapy: the past, the present and the future. Clin Oncol
2007;19:790e799.
[5] Putta S, Andreyev HJN. Faecal incontinence: a late side-effect
of pelvic radiotherapy. Clin Oncol 2005;17:469e477.
[6] Andreyev J. Gastrointestinal complications of pelvic radio-
therapy: are they of any importance? Gut
2005;54:1051e1054.
[7] Abayomi J, Kirwan J, Hackett A. The prevalence of chronic
radiation enteritis following radiotherapy for cervical or
endometrial cancer and its impact on quality of life. Eur J
Oncol Nursing 2009;13:262e267.Questionnaire Provides a Validated Screening Tool to Detect Chronic
Clinical Oncology (2016), http://dx.doi.org/10.1016/j.clon.2016.06.004
S. Taylor et al. / Clinical Oncology xxx (2016) 1e9 9[8] Teo M, Sebag-Monteﬁore D, Donnellan C. Prevention and
management of radiation-induced late gastrointestinal
toxicity. Clin Oncol 2015;27:656e667.
[9] Muls AWL, Shaw C, Andreyev J. Managing gastrointestinal
symptoms after cancer treatment: a practical approach for
gastroenterologists. Frontline Gastroenterol 2013;4:57e68.
[10] Benton B, Norton C, Lindsay J, Dolan S, Andreyev H. Can
nurses manage gastrointestinal symptoms arising from pelvic
radiation disease? Clin Oncol 2011;23:538e551.
[11] Henson C, Davidson S, Ang Y, et al. Structured gastroentero-
logical intervention and improved outcome for patients with
chronic gastrointestinal symptoms following pelvic radio-
therapy. Support Care Cancer 2013;21:2255e2265.
[12] National Cancer Institute. Common Terminology Criteria for
Adverse Events 2015.
[13] Farnell DJ, Mandall P, Anandadas C, et al. Development of a
patient-reported questionnaire for collecting toxicity data
following prostate brachytherapy. Radiother Oncol
2010;97:136e142.
[14] LENT SOMA tables. Radiother Oncol 1995;35:17e60.
[15] Guyatt G, Mitchell A, Irvine E, et al. A new measure of health
status for clinical trials in inﬂammatory bowel disease.
Gastroenterology 1989;96:804e810.
[16] Kulich KR, Madisch A, Pacini F, et al. Reliability and validity of
the Gastrointestinal Symptom Rating Scale (GSRS) and Qual-
ity of Life in Reﬂux and Dyspepsia (QOLRAD) questionnaire in
dyspepsia: a six-country study. Health Qual Life Outcomes
2008;6:12.
[17] Vaizey C, Carapeti E, Cahill J, Kamm M. Prospective compari-
son of feacal incontinence grading systems. Gut
1999;44:77e80.
[18] Willis G. Cognitive interviewing: a tool for improving ques-
tionnaire design. Thousand Oaks: Sage; 2005.
[19] Blair J, Conrad F, Ackermann AC, Claxton G. The effect of
sample size on cognitive interview ﬁndings. Proceedings of
the American Statistical Association2006.
[20] Irwin D, Varni J, Yeatts K, DeWalt D. Cognitive interviewing
methodology in the development of a pediatric item back: aPlease cite this article in press as: Taylor S, et al., The Three-item ALERT-B
Gastrointestinal Symptoms after Pelvic Radiotherapy in Cancer Survivors,patient reported outcomes measurement information system
(PROMIS) study. Health Qual Life Outcomes 2009;7:1e10.
[21] Dimen€as E, Glise H, Hallerb€ack B, Hernqvist H, Svedlund J,
Wiklund I. Well-being and gastrointestinal symptoms among
patients referred to endoscopy owing to suspected duodenal
ulcer. Scand J Gastroenterol 1995;30:1046e1052.
[22] Presser S, Blair J. Sociological methodological. Washington DC:
American Sociological Association; 1994.
[23] Braun V, Clarke V. Using thematic analysis in psychology. Qual
Res Psychol 2006;3:77e101.
[24] Fayers P, Hand D. Factor analysis, causal indicators and quality
of life. Qual Life Res 1997;6:139e150.
[25] Armstrong JS, Soelberg P. On the interpretation of factor
analysis. Psychol Bull 1968;70:361.
[26] Beatty PC, Willis GB. Research synthesis: the practice of
cognitive interviewing. Public Opinion Q 2007;71:287e311.
[27] Ahmed N, Bestall JC, Payne SA, Noble B, Ahmedzai SH. The use
of cognitive interviewing methodology in the design and
testing of a screening tool for supportive and palliative care
needs. Support Care Cancer 2009;17:665e673.
[28] Stone EF, Stone DL, Gueutal HG. Inﬂuence of cognitive ability
on responses to questionnaire measures: measurement pre-
cision and missing response problems. J Appl Psychol
1990;75:418.
[29] Borgers N, Sikkel D, Hox J. Response effects in surveys on
children and adolescents: the effect of number of response
options, negative wording, and neutral mid-point. Qual Quant
2004;38:17e33.
[30] Krosnick JA, Narayan S, Smith WR. Satisﬁcing in surveys:
initial evidence. New Direct Eval 1996;1996:29e44.
[31] Kn€auper B, Belli RF, Hill DH, Herzog AR. Question difﬁculty
and respondents’ cognitive ability: the effect on data quality.
J Ofﬁc Stat Stockholm 1997;13:181e199.
[32] Rho C SR. How Much can you trust the answers you get using
cognitive interviews?: American Association for the Public
Opinion Research: Bureau of Labor Statistics, Ofﬁce of Survey
Methods Research. Washington DC 20212 USA 2003.Questionnaire Provides a Validated Screening Tool to Detect Chronic
Clinical Oncology (2016), http://dx.doi.org/10.1016/j.clon.2016.06.004
